[New approaches in progressive kidney diseases]

Area of Science:

• Nephrology and Pathology
• Molecular Biology
• Translational Medicine

Context:

• Renal fibrosis, characterized by scar tissue accumulation, is the common endpoint for diverse chronic kidney diseases (CKD).
• Effective treatments for CKD are limited, highlighting the need for novel therapeutic strategies targeting fibrosis.
• Preclinical research faces significant hurdles in identifying and validating antifibrotic agents.

Purpose:

• To review the challenges in preclinical identification and testing of therapeutic targets for renal fibrosis.
• To discuss obstacles in translating preclinical findings into effective clinical treatments for CKD.
• To present preclinical evidence for novel molecules implicated in renal fibrosis.

Summary:

• Discusses the difficulties in preclinical evaluation of potential treatments for renal fibrosis.
• Highlights issues in translating research findings from preclinical models to human CKD patients.
• Examines the roles of platelet-derived growth factors (PDGF), C5a, and peroxisome proliferator-activated receptor-α (PPAR-α) in renal fibrosis.

Impact:

• Identifies critical gaps in the preclinical assessment of antifibrotic therapies for CKD.
• Provides insights into the translational challenges for novel renal fibrosis treatments.
• Highlights promising molecular targets, including PDGF, C5a, and PPAR-α, for future therapeutic development in kidney disease.